NASDAQ: ACAD - ACADIA Pharmaceuticals Inc.

Yield per half year: -46.22%
Sector: Healthcare

Share chart ACADIA Pharmaceuticals Inc.


About

ACADIA Pharmaceuticals Inc., биофармацевтическая компания, специализируется на разработке и коммерциализации низкомолекулярных препаратов, предназначенных для удовлетворения неудовлетворенных медицинских потребностей при заболеваниях центральной нервной системы.

More details
Компания предлагает НУПЛАЗИД (пимавансерин) для лечения галлюцинаций и бреда, связанных с психозом при болезни Паркинсона; Трофинетид, новый синтетический аналог для лечения синдрома Ретта; ACP-044, новый первый в своем классе неопиоидный анальгетик для перорального приема для лечения острой и хронической боли; и ACP-319, положительный аллостерический модулятор мускаринового рецептора для лечения когнитивных функций и шизофрении. Он также разрабатывает пимавансерин для лечения психоза, связанного с деменцией, и в качестве дополнительного лечения шизофрении; и пимавансерин в качестве дополнительного лечения большого депрессивного расстройства. ACADIA Pharmaceuticals Inc. была основана в 1993 году, ее штаб-квартира находится в Сан-Диего, Калифорния.


Main settings

P/S 17.52
P/BV 8.5
EV/EBITDA -23.61
EBITDA -0.2438
Цена ао 15.08
Сайт https://www.acadia-pharm.com
Число акций ао 0.16382 млрд
Выручка 0.3391
Див.доход ао 0
ISIN US0042251084
Change price per day: 0% (15.37)
Change price per week: +0.4575% (15.3)
Change price per month: +3.43% (14.86)
Change price per 3 month: -17.94% (18.73)
Change price per half year: -46.22% (28.58)
Change price per year: -36.14% (24.07)
Change price per 3 year: -12.07% (17.48)
Change price per 5 year: -27.05% (21.07)
Change price per year to date: -50.91% (31.31)


All parameters ⇨

Grade

Underestimation

Title Value Grade
P/S 17.52 1
P/BV 8.5 1
P/E 0 0
EV/EBITDA -23.61 0
Total:

Efficiency

Title Value Grade
ROA, % -9.17 0
ROE, % -14.73 0
Total:

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total:

Debt

Title Value Grade
Debt/EBITDA -0.8437 10
Total:

Growth impulse

Title Value Grade
Profit growth, % -78.27 0
Share price growth, % -41.99 0
Dividend growth, % 0 0
Total:

Insider trading

Transaction date Date of disclosure Insider Type Price Volume Quantity Share before, % Share after, % Document
26.02.2024 27.02.2024 DAVIS STEPHEN
CEO
Sale 24.67 137 585 5577 0 0 link
26.02.2024 27.02.2024 Kihara James
PRINCIPAL ACCOUNTING OFFICER
Sale 24.67 11 694 474 0 0 link
26.02.2024 27.02.2024 Teehan Brendan
EVP, COO, HEAD OF COMMERCIAL
Sale 24.67 15 394 624 0 0 link
26.02.2024 27.02.2024 Schneyer Mark C.
EVP, CHIEF FINANCIAL OFFICER
Sale 24.67 19 045 772 0 0 link
08.01.2024 09.01.2024 KIM AUSTIN D.
EVP,General Counsel, Secretary
Sale 29.96 17 676 590 0 0 link
08.01.2024 09.01.2024 Teehan Brendan
EVP, COO, Head of Commercial
Sale 29.96 21 901 731 0 0 link
08.01.2024 09.01.2024 DAVIS STEPHEN
CEO
Sale 29.96 111 811 3732 0 0 link
21.08.2023 23.08.2023 Schneyer Mark C.
EVP, Chief Financial Officer
Sale 29 290 000 10000 0 -0.01 link
12.07.2023 13.07.2023 DAVIS STEPHEN
CEO
Sale 25.05 1 380 360 55104 0 -0.03 link
11.07.2023 13.07.2023 DAVIS STEPHEN
CEO
Sale 25 412 450 16498 0 -0.01 link
01.05.2023 02.05.2023 DAVIS STEPHEN
CEO
Sale 21.18 165 331 7806 0 0 link
01.05.2023 02.05.2023 Teehan Brendan
EVP, COO, Head of Commercial
Sale 21.18 11 607 548 0 0 link
01.05.2023 02.05.2023 KIM AUSTIN D.
EVP,General Counsel, Secretary
Sale 21.18 19 422 917 0 0 link
29.04.2023 02.05.2023 DAVIS STEPHEN
CEO
Buy 21.38 334 063 15625 0 0.01 link
29.04.2023 02.05.2023 Teehan Brendan
EVP, COO, Head of Commercial
Buy 21.38 33 502 1567 0 0 link
06.04.2023 07.04.2023 KIM AUSTIN D.
EVP,General Counsel, Secretary
Sale 18.16 26 441 1456 0 0 link
06.04.2023 07.04.2023 DAVIS STEPHEN
CEO
Sale 18.16 155 849 8582 0 -0.01 link
06.04.2023 07.04.2023 Schneyer Mark C.
EVP, Chief Financial Officer
Sale 18.16 34 795 1916 0 0 link
06.04.2023 07.04.2023 Kihara James
Principal Accounting Officer
Sale 18.16 12 730 701 0 0 link
06.04.2023 07.04.2023 Teehan Brendan
EVP, COO, Head of Commercial
Sale 18.16 31 798 1751 0 0 link
09.06.2022 10.06.2022 Schneyer Mark C.
EVP, Chief Financial Officer
Sale 17.91 11 695 653 0 0 link
08.06.2022 10.06.2022 Schneyer Mark C.
EVP, Chief Financial Officer
Buy 17.09 32 351 1893 0 0 link
08.04.2022 11.04.2022 Kihara James
Principal Accounting Officer
Sale 27.05 27 726 1025 0 0 link
23.02.2022 25.02.2022 DAVIS STEPHEN
CEO
Sale 23.8 93 486 3928 0 0 link
23.02.2022 25.02.2022 DAVIS STEPHEN
CEO
Buy 25.6 280 247 10945 0 0.01 link
23.02.2022 25.02.2022 KIM AUSTIN D.
EVP & General Counsel
Sale 23.8 18 612 782 0 0 link
23.02.2022 25.02.2022 KIM AUSTIN D.
EVP & General Counsel
Buy 25.6 56 664 2213 0 0 link
23.02.2022 25.02.2022 Teehan Brendan
EVP, COO, Head of Commercial
Sale 23.8 11 234 472 0 0 link
23.02.2022 25.02.2022 Teehan Brendan
EVP, COO, Head of Commercial
Buy 25.6 28 319 1106 0 0 link
06.01.2022 10.01.2022 DAVIS STEPHEN
CEO
Sale 23.05 85 700 3718 0 0 link
06.01.2022 10.01.2022 Stankovic Srdjan R.
President
Sale 23.05 44 648 1937 0 0 link
06.01.2022 10.01.2022 KIM AUSTIN D.
EVP & General Counsel
Sale 23.05 13 231 574 0 0 link
06.01.2022 10.01.2022 Teehan Brendan
EVP, COO, Head of Commercial
Sale 23.05 12 401 538 0 0 link
22.11.2021 23.11.2021 Stankovic Srdjan R.
President
Sale 19.01 53 285 2803 0 0 link

Main owners

Institutions Volume Share, %
Baker Brothers Advisors, LLC 42864612 26.01
Vanguard Group Inc 13396009 8.13
Blackrock Inc. 11410483 6.93
RTW Investments LP 11253551 6.83
State Street Corporation 6465026 3.92
EcoR1 Capital, LLC 5991479 3.64
FMR, LLC 5265358 3.2
Price (T.Rowe) Associates Inc 5178509 3.14
Shaw D.E. & Co., Inc. 3754598 2.28
Fred Alger Management, LLC 3176775 1.93

Contained in ETF

ETF Share, % Profitability for 1 year, % Dividends, %
PSYK ETF 4.28
iShares Neuroscience and Healthcare ETF 4.51 0.03

Similar companies



Company management

Head Job title Payment Year of birth
Mr. James K. Kihara VP, Chief Accounting Officer & Corporate Controller N/A 1981 (43 years)
Ms. Julie Fisher Senior Vice President of Marketing & Commercial Strategy N/A
Mr. Stephen R. Davis J.D. President, CEO & Director 1.46M 1961 (63 years)
Mr. Mark C. Schneyer Executive VP & CFO 701.03k 1975 (49 years)
Mr. Brendan P. Teehan Executive VP, COO & Head of Commercial 724.31k 1969 (55 years)
Mr. Rob Ackles Senior VP & Chief People Officer N/A
Ms. Holly Valdiviez Senior VP & Head of Sales N/A
Mr. Albert S. Kildani Senior Vice President of Investor Relations & Corporate Communications N/A
Mr. Benir Ruano Senior Vice President of Technical Development & Operations N/A
Ms. Jennifer J. Rhodes J.D. Executive VP, Chief Legal Officer & Secretary N/A 1970 (54 years)

About company

Address: United States, San Diego, CA , 12830 El Camino Real - open in Google maps, open in Yandex maps
Website: https://www.acadia-pharm.com